EN DE
Watch Milestone Scientific for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Milestone Scientific (MLSS) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Milestone Scientific stock $0.24, price $0.29, that is 19.1% below the price, quality 32 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

MS Milestone Scientific logo Thin data Nov 10, 2026

Milestone Scientific

MLSS · US
Expensive, weak quality

Our calculation puts a fair price 19% below what the stock costs today.

Low debt
Revenue last quarter +22% vs. a year ago.
Expensive Growth (revenue 5y +10.5 %/yr in USD)
Fair value $0.2362 · Overvalued
Quality 32/100
Loss-making · -44.0% net margin (TTM)
Negative free cash flow
Trails peers (1/10)
Narrow moat 10/100 · thin data
Thin data
Estimate
Watch Milestone Scientific for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$2.71 $0.2464 Fair Value $0.2362 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.2464 – $2.71 · fair‑value band $0.1772 – $0.2953 · the $0.2919 price screens above the $0.2362 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Milestone Scientific in your weekly email

Every Wednesday you see whether Milestone Scientific is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Milestone Scientific Inc., a biomedical technology company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical and dental use in the United States, China, and internationally. It operates through Dental and Medical segments.

Show moreShow less

The company provides the Wand, a single use disposable handpiece device for dental procedures that require local anesthetic under the CompuDent and STA Single Tooth Anesthesia System names.

It also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection.

In addition, the company provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications.

Further, it offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines.

Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.

Stock analysis

Milestone Scientific (MLSS) currently trades at $0.2919, while our estimate is $0.2362, 19% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.1772 (bear) to $0.2953 (bull), the price of $0.2919 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Milestone Scientific reported revenue of $9.0M in FY2025 versus $10.3M in FY2021, a compound −3.4%/yr. Reported net income was −$5.7M in FY2025.

Key figures

Market cap $27.2M Micro · P/S ratio 3.03 · EPS (TTM) $−0.0400 · Net margin −44.0% · Return on equity −122% · Return on assets (EBIT) −61.2% (5-year average) · Operating margin −37.4% · Revenue (TTM) $9.4M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 47% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −19%, MLSS screens cheaper than that median.

Fair Value

Bear $0.1772 Fair Value $0.2362 Bull $0.2953
Price $0.2919 · Downside -19.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 37
How much profit the company makes from its sales and capital
Quality Growth 28
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 45
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 26
How calm the share price moves, does not count
Price momentum 13
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 9
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+4.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.5%
Start year 2020 (pandemic). Over 10 years: −0.6% a year
Revenue growth 29 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−137.1% (2020) → −63.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

MLSS screens overvalued: fair value 19% below the price. Compare with Intuitive Surgical, Inc →

Compare Milestone Scientific with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 196 stocks

Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −19.1% · Below median
Profitability
Return on assets −73.3% · Bottom 25%
Net margin (12 months) −44.0% · Bottom 25%
Operating margin (12 months) −37.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 22.3% · Top 25%
Balance sheet
Debt / equity 0.28× · Highest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 9.66× · Priciest 25%
P/S (12 months) 2.89× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)8 · sector 21
FUTURE (revenue growth)100 · sector 40
PAST (return on equity)0 · sector 26
HEALTH (low debt)86 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.08 $131.27 +46% vs MLSS
EssilorLuxottica Société anonyme EL €187.60 €196.22 +5% vs MLSS
Intuitive Surgical, Inc ISRG $450.04 $353.90 −21% vs MLSS
Medline Inc MDLN $40.91 $28.59 −30% vs MLSS
Alcon Inc ALC CHF 61.88 CHF 34.06 −45% vs MLSS
Becton, Dickinson and Company BDX $212.61 $97.80 −54% vs MLSS
Straumann Holding STMN CHF 106.85 CHF 45.50 −57% vs MLSS
West Pharmaceutical Services, Inc WST $412.55 $139.22 −66% vs MLSS
Sartorius Stedim Biotech S.A DIM €223.40 €54.82 −75% vs MLSS
Sartorius Aktiengesellschaft SRT €227.00 €42.50 −81% vs MLSS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Milestone Scientific: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Milestone Scientific Fair Value". https://www.fairvalue-calculator.com/stock/MLSS

Frequently asked questions

Is Milestone Scientific (MLSS) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.2362 versus a price of $0.2919, about 19% lower (overvalued).
What is the fair value of MLSS?
Our estimate for Milestone Scientific is $0.2362 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.2919.
What is the quality score of MLSS?
Milestone Scientific has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Milestone Scientific (MLSS)?
Our calculated price target is the estimate of $0.2362 (as of Nov 10, 2026). Cautious scenario $0.1772, optimistic scenario $0.2953. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Milestone Scientific stock forecast for 2026?
Our estimate puts fair value at $0.2362, about 19% lower versus a price of $0.2919 (overvalued). Cautious scenario $0.1772, optimistic scenario $0.2953. The calculation is refreshed regularly with new filings.
What is the revenue of Milestone Scientific (MLSS)?
Milestone Scientific reported trailing-twelve-month revenue of about $9.4M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Milestone Scientific (MLSS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Milestone Scientific it is $0.2362 per share (as of Nov 10, 2026), against a price of $0.2919.
Is Milestone Scientific stock overvalued or undervalued in 2026?
As of Nov 10, 2026, MLSS trades above its calculated fair value: price $0.2919, fair value $0.2362, a gap of about −19% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MLSS?
No. The price is what the market pays today ($0.2919); the fair value is what the company's own numbers justify ($0.2362). For Milestone Scientific the two are $0.0557 per share apart. That gap is exactly why we show both numbers side by side.
How much is Milestone Scientific worth?
The market values Milestone Scientific at about $27.2M (market capitalisation, as of Nov 10, 2026). Per share that is $0.2919; our models calculate a fair value of $0.2362 per share.
What do the bullish and bearish scenarios say about MLSS?
Our models span a range for Milestone Scientific: cautious scenario $0.1772, base $0.2362, optimistic $0.2953 per share (as of Nov 10, 2026, price $0.2919). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Milestone Scientific (MLSS)?
Balance-sheet figures for Milestone Scientific (as of Nov 10, 2026): return on equity −121.7%, debt of 0.28 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is MLSS from its 52-week high?
Milestone Scientific trades at $0.2919, about 47% below its 52-week high of $0.5530 and 18% above the low of $0.2464 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2362 is for.
Which stocks are comparable to Milestone Scientific?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Milestone Scientific stock attractive at the current price?
The data as of Nov 10, 2026: price $0.2919, calculated fair value $0.2362 (−19%), Quality Score 32/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Milestone Scientific itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Milestone Scientific (MLSS)?
The closing price on Nov 10, 2026 was $0.2919. Our estimate is $0.2362, about 19% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Milestone Scientific right now?
Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Milestone Scientific

How large is the market capitalisation of Milestone Scientific (MLSS)?
The market capitalisation of Milestone Scientific is $27.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Milestone Scientific (MLSS)?
The price-to-sales ratio of Milestone Scientific is 3.03 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Milestone Scientific (MLSS)?
Earnings per share at Milestone Scientific are $−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Milestone Scientific (MLSS)?
The net margin of Milestone Scientific is −44.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Milestone Scientific (MLSS)?
The return on equity (ROE) of Milestone Scientific is −122% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Milestone Scientific (MLSS)?
On an EBIT basis the return on assets of Milestone Scientific is −61.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Milestone Scientific (MLSS)?
The operating margin of Milestone Scientific is −37.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Milestone Scientific (MLSS)?
Revenue at Milestone Scientific is growing +22.3% versus a year earlier (3y avg +0.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Milestone Scientific (MLSS) generate?
The free cash flow of Milestone Scientific is −$2.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Milestone Scientific (MLSS) hold?
Milestone Scientific holds more cash than debt, $92.4K net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Milestone Scientific in the live analysis

One click puts Milestone Scientific on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.